Thank you

This live web event has ended. Thank you for attending.

Description

Platform Presentations
Please see the Resources tab for full abstracts and co-authors.

Platform 1: Neurodegenerative: Alzheimer
Moderators: Annie Hiniker, MD, PhD and Richard Perrin, MD, PhD
8:00 am – 8:15 am
1. Autopsy findings versus biomarker outcomes in a clinical trial of anti-Aβ therapies in dominantly inherited Alzheimer disease

• Charles Chen, PhD

8:15 am – 8:30 am
2. Cognitive impairment in Primary Age-Related Tauopathy: A community-based autopsy study

• Sonal Agrawal, PhD

8:30 am – 8:45 am
3. Shared Transcriptional Changes in Neurons with Tau Pathology in PART and AD

• Meaghan Morris, MD, PhD

8:45 am – 9:00 am
4. Brain Metal Concentrations and Alzheimer's Disease Neuropathological Change in Total Joint Arthroplasty Patients at Autopsy

• Blake Ebner, MD, PhD

9:00 am – 9:15 am
5. Clinical and pathological correlates of ARTAG in the NACC Neuropathology Data set

• Peter Nelson, MD, PhD

9:15 am – 9:30 am
6. Environmental-Pathology Interactions in Neurodegenerative Disease Dementia

• Boram Kim, MD

9:30 am – 9:45 am
7. Early Alzheimer’s Disease-Like Neuropathology in the Nonhuman Primate Chlorocebus Aethiops: Relationships with Age and Physical Function>

• William Harrison, MD

9:45 am – 10:00 am
8. Machine learning analysis of Amyloid-β pathologies and their correlations in 131 cases from an Alzheimer’s Disease Research Center

• Brittany Dugger, PhD

Platform 3: Neurodegenerative: FTLD/Lewy body/Parkinson, Trauma, Vascular
Moderators: Arline Faustin, MD and Derek Oakley, MD, PhD
1:30 pm – 1:45 pm
17. ANXA11 is a significant aggregating disease protein in FTLD-TDP Type C and related TDP-43 proteinopathies

• John Robinson

1:45 pm – 2:00 pm
18. Cellular Dissection of Multiple System Atrophy

• Daniel Mordes, MD, PhD

2:00 pm – 2:15 pm
19. CSF Alpha Synuclein Seed Amplification Assay Performance in Relation to Neuropathological Staging of Lewy Body Diseases and Co-pathologies

• Purvi Patel, MD, PhD

2:15 pm – 2:30 pm
20. Neuropathology Indicates Limitations to Clinical Biomarker Based Staging of Lewy Body Disorders

• Thomas Beach, MD, PhD, FRCPC

2:30 pm – 2:45 pm
21. Small Vessel Disease in the Brains of Young Military Service Members

• David Priemer, MD

2:45pm pm – 3:00 pm
22. Differential detection of TDP-43 in FTLD-TDP Type C using antibodies targeting distinct TDP-43 phosphorylated sites

• Laura Cracco, PhD

3:00 pm – 3:15 pm
23. An analysis of cervical dorsal root ganglia hemorrhage in infant decedents

• Jared Ahrendsen, MD, PhD

3:15 pm – 3:30 pm
24. Diverse genomic alterations in single neurons after chronic brain trauma

• Michael Miller, MD, PhD

Parisi Lecture:
Viral Infections, Cognitive Impairments, and Neurodegeneration: Lessons from HIV
Susan Morgello, MD
Mount Sinai Medical Center, New York, NY

Biography
Dr. Susan Morgello is Professor of Neurology, Pathology, and Neuroscience at the Icahn School of Medicine at Mount Sinai, and serves as Chief of the Division of Neuro-Infectious Diseases in the Department of Neurology. She is founder and principal investigator of the Manhattan HIV Brain Bank (MHBB), a research resource that has continuously operated since 1998 in her home town of New York City. The MHBB’s primary mission is to support neuroHIV research, and in doing so, provide a mechanism by which scientists and patients can collaborate to improve the lives of people with HIV. The MHBB conducts New York City’s largest multidisciplinary cohort study of nervous system disorders in people with and at risk for HIV, and hosts a biorepository/brain bank tied to information obtained in prospective study. Dr. Morgello’s commitment to HIV research began in the 1980s, when she returned to New York from her medical training at Duke University to witness the tragedy and horrors of the AIDS pandemic, manifest in both the dementing disorders and fatal systemic diseases associated with the virus.

Learning Objectives
1. Describe 4 general mechanisms by which HIV causes or contributes to cognitive impairment, citing evidence to support each pathway.
2. Describe HIV brain pathologies, and the impacts of antiretroviral therapies on the relationship between neuropathology and behavior.
3. Discuss research findings related to abnormal deposition of tau and amyloid in the brains of people aging with HIV.
4. Identify and contrast aspects of the HIV and SARS-CoV-2 life cycles that contribute to neuropathogenesis.

Abstract
Human immunodeficiency virus (HIV) has disparate impact on underserved and marginalized populations, with CNS disorders prominent in its manifestations. From the profound dementias seen in untreated, natural history disease, to the milder cognitive deficits that have always been recognized, but now play an outsized role in the burdens of people on antiretroviral therapy, HIV demonstrates protean ability to cause CNS dysfunction. This talk will review the neuropathology and neurobiology of HIV as it pertains to cognitive impairment, review the issue of whether, as a chronic viral infection, HIV predisposes to development of neurodegenerative pathologies, and examine whether lessons learned from the HIV pandemic have relevance to ongoing investigations of SARS-CoV-2-related CNS dysfunction.

References
1 .Bruno F, et al. Alzheimer’s disease as a viral disease: Revisiting the infectious hypothesis. Ageing Research Reviews 2023, 91:102068
2. Komaroff AL. Can infections cause Alzheimer Disease? JAMA 2020, 324(3):239-240
3. Morgello S. HIV Neuropathology. In Handbook of Clinical Neurology, Vol 152 The Neurology of HIV infection, Bruce J Brew, ed. 2018, pp3-19.
4. Morgello S. Coronaviruses and the central nervous system. Journal of Neurovirology 2020, 26:459-473
5. Morgello S, et al. HIV disease duration, but not active brain infection, predicts cortical amyloid beta deposition. AIDS 2021, 35:1403-1412.
6. Murray J, et al. Frontal lobe microglia, neurodegenerative protein accumulation, and cognitive function in people with HIV. Acta Neuropathologica 2022, 10:6